ID: ALA5271481

Max Phase: Preclinical

Molecular Formula: C19H23F2N4O8P

Molecular Weight: 504.38

Representations

Canonical SMILES:  COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1

Standard InChI:  InChI=1S/C19H23F2N4O8P/c1-11(16(27)30-2)24-34(29,33-12-6-4-3-5-7-12)31-10-13-15(26)19(20,21)17(32-13)25-9-8-14(22)23-18(25)28/h3-9,11,13,15,17,26H,10H2,1-2H3,(H,24,29)(H2,22,23,28)/t11-,13+,15+,17+,34?/m0/s1

Standard InChI Key:  YLCJWKICCVEVRK-SLDUBEPBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 504.38

Molecular Weight (Monoisotopic): 504.1222

AlogP: 1.07

#Rotatable Bonds: 9

Polar Surface Area: 164.23

Molecular Species: NEUTRAL

HBA: 11

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.22

CX Basic pKa:

CX LogP: 0.29

CX LogD: 0.29

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.33

Np Likeness Score: 0.50

References

1. Zhang L, Qi K, Xu J, Xing Y, Wang X, Tong L, He Z, Xu W, Li X, Jiang Y..  (2023)  Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.,  66  (6): [PMID:36867101] [10.1021/acs.jmedchem.3c00006]

Source

Source(1):

• Scientific Literature